Tonix Pharmaceuticals Holding (TNXP) Change in Accured Expenses (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Change in Accured Expenses for 16 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 47.93% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 352.38% increase from a year earlier, with the FY2025 full-year figure at $11.7 million, up 886.97% from the prior year.
• Change in Accured Expenses was $1.8 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from -$2.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $10.1 million in Q4 2025, with the low at -$3.0 million in Q1 2023.
• Average Change in Accured Expenses over 5 years is $867444.4, with a median of $1.1 million recorded in 2024.
• The largest YoY upside for Change in Accured Expenses was 581.98% in 2023 against a maximum downside of 179.74% in 2023.
• Over 5 years, Change in Accured Expenses stood at $2.2 million in 2022, then jumped by 100.54% to $4.4 million in 2023, then slumped by 65.02% to $1.5 million in 2024, then soared by 551.29% to $10.1 million in 2025, then slumped by 82.63% to $1.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.8 million (Q2 2026), -$2.1 million (Q1 2026), and $10.1 million (Q4 2025), per Business Quant data.